You are here: Industry Insights > Market News > India to assess side effects of COVID-19 vaccine

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

PVP-K30-----pharma excipients(CAS No.9003-39-8)

Tobramycin

Povidone iodine 20% powder

Povidone iodine 10% powder

SULBACTAM SODIUM STERILE

Food Additives Bulk Sucralose Neotame Advantame Powder

India to assess side effects of COVID-19 vaccine

expresspharmaApril 12, 2021

Tag: India , COVID-19 vaccine , side effect , blood clot

Favorites

A panel of Indian experts is investigating if there are any domestic cases of blood clotting, even mild ones, as a side effect of the two COVID-19 vaccines being administered in the country, reported Mint, a financial newspaper.

India is currently administering AstraZeneca’s COVID-19 vaccine and a shot developed at home by Bharat Biotech.

Several countries in Europe have announced restrictions on the use of the AstraZeneca vaccine in younger people, after a link was found to very rare blood clots, mostly in women under 60 years of age within two weeks of vaccination.

Previous:Remdesivir’s price must not be more than Rs 1400 per vial: Maha Health Minister

Next:Biogen and Bio-Thera enter licencing agreement for arthritis biosimilar

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

India to assess side effects of COVID-19 vaccine | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Factory Free Sample Bulk Food Pure Grade Natural India Herbal Plant Extract Madder Root Extract

Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality

Indian Trum etflower Seed Extract

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect by hualan biological

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect

Evening Primrose Oil (OEM/ODM) | Evening Primrose Oil From India / natural Evening Prim rose Oil

Mifepristone (INDIA DMF)

100% Pure Freeze Dried Black Berry Anthocyanin Juice Indian Instant Fruit Blackberry Powder

Top Quality Indian Bread P.E.

PHENOXYMETHYL PENICILLIN POTASSIUM

India to assess side effects of COVID-19 vaccine

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

You may likeMore>>

You may like
More>>